PubMed

Calcifediol (25-hydroxyvitamin D3) in the treatment of uremic bone disease.

Teitelbaum SL.

Ann Intern Med. 1981 Mar;94(3):404-5. No abstract available. PMID: 6894359 [PubMed - indexed for MEDLINE]Related articles

[Treatment with 1-alpha hydroxy vitamin D3 of bone disease in hemodialysis. Therapeutic results and complications]

García de Vinuesa S, Barril G, Luño J, Alles A, Jofré R, Pérez García R, Olivas E, López Gómez JM, Valderrábano F.

Rev Clin Esp. 1980 Dec 15;159(5):317-22. Spanish. No abstract available. PMID: 7221095 [PubMed - indexed for MEDLINE]Related articles

The effects of calciferol and its metabolites on patients with chronic renal failure. II. Calcitriol, 1 alpha-hydroxyvitamin D3, and 24,25-dihydroxyvitamin D3.

Voigts AL, Felsenfeld AJ, Llach F.

Arch Intern Med. 1983 Jun;143(6):1205-11. Review.PMID: 6344827 [PubMed - indexed for MEDLINE]Related articles

[Renal osteodystrophy in children. Therapy with 1,25-dihydroxy-cholechalciferol (author's transl)]

Bulla M, Delling G, Benz-Bohm G, Stock GJ, Sánchez de Reutter A, Ziegler R, Lühmann H, Severin M, Kalbitzer E, Manegold C.

Klin Wochenschr. 1980 May 16;58(10):511-9. German. PMID: 7392529 [PubMed - indexed for MEDLINE]Related articles

1,25-dihydroxycholecalciferol. Effect on skeletal lesions and plasma parathyroid hormone levels in uremic osteodystrophy.

Brickman AS, Sherrard DJ, Jowsey J, Singer FR, Baylink DJ, Maloney N, Massry SG, Norman AW, Coburn JW.

Arch Intern Med. 1974 Nov;134(5):883-8. No abstract available. PMID: 4613310 [PubMed - indexed for MEDLINE]Related articles

1,25 dihydroxyvitamin D3 and osteomalacia: some unanswered questions.

Velentzas C, Oreopoulos DG.

Int J Artif Organs. 1980 Nov;3(6):313-5. No abstract available. PMID: 6893977 [PubMed - indexed for MEDLINE]Related articles

Requirements of vitamin D metabolites in patients with renal disease.

Massry SG.

Am J Clin Nutr. 1980 Jul;33(7):1530-5. No abstract available. PMID: 6893103 [PubMed - indexed for MEDLINE]Related articlesFree article

[Effects of treatment with 1--alpha-hydroxyvitamin D3 in osteodystrophy in uremic patients undergoing periodical hemodialysis]

Albertazzi A, Palmieri PF, Del Rosso G, Spisni C, Evangelista M.

Minerva Nefrol. 1980 Oct-Dec;27(4):631-3. Italian. No abstract available. PMID: 7254690 [PubMed - indexed for MEDLINE]Related articles

Clinical effects of 1,25-dihydroxyvitamin D3 in uremic patients with overt osteodystrophy.

Brickman AS, Coburn JW, Sherrard DJ, Wong EG, Norman AW, Singer FR.

Contrib Nephrol. 1980;18:29-41. No abstract available. PMID: 7353378 [PubMed - indexed for MEDLINE]Related articles

Use of 1,25(OH)2-vitamin D3 in prevention of renal osteodystrophy: preliminary observations.

Baker LR, Muir JW, Cattell WR, Tucker KA, Sharman VL, Goodwin FJ, Marsh FP, Hately W, Morgan AG, de Saintonge DM.

Contrib Nephrol. 1980;18:147-51.PMID: 7353373 [PubMed - indexed for MEDLINE]Related articles

Does uremic bone disease warrant early treatment with calcitriol?

Chesney RW.

Arch Intern Med. 1980 Aug;140(8):1016-7. No abstract available. PMID: 6893117 [PubMed - indexed for MEDLINE]Related articles

Short-term effects of 1,25-dihydroxycholecalciferol on disordered calcium metabolism of renal failure.

Brickman AS, Coburn JW, Norman AW, Massry SG.

Am J Med. 1974 Jul;57(1):28-33. Review. No abstract available. PMID: 4600292 [PubMed - indexed for MEDLINE]Related articles

24,25 dihydroxycalciferol: assay in non-anephric patients on chronic haemodialysis and assessment of its possible pathophysiological role in renal osteodystrophy.

Lambrey G, Nguyen TM, Fournier A, Sebert JL, Kassouf J, de Fremont JF, Marie P, Meunier P, Caillens C, Gueris J, Garabedian M, Balsan S.

Proc Eur Dial Transplant Assoc. 1980;17:548-56. No abstract available. PMID: 6972530 [PubMed - indexed for MEDLINE]Related articles

Effects of 6 months therapy with 1,25 (OH)2D3 on bone disease of dialysis patients.

Malluche HH, Goldstein DA, Massry SG.

Contrib Nephrol. 1980;18:98-104. No abstract available. PMID: 7353383 [PubMed - indexed for MEDLINE]Related articles

[Therapeutic use of vitamin D, its derivatives and their analogs]

Vagneur JP, Argemi B.

Diabete Metab. 1982 Mar;8(1):65-7. French. No abstract available. PMID: 6980150 [PubMed - indexed for MEDLINE]Related articles

Short-term effects of vitamin D3 and 1,25-dihydroxyvitamin D3 on osteomalacia in uremic rats fed a low calcium-low-phosphorus diet.

Weisbrode SE.

Am J Pathol. 1981 Jul;104(1):35-40. No abstract available. PMID: 6266257 [PubMed - indexed for MEDLINE]Related articlesFree article

Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.

Massry SG, Goldstein DA, Malluche HH.

Kidney Int. 1980 Oct;18(4):409-18. Review. No abstract available. PMID: 7014981 [PubMed - indexed for MEDLINE]Related articles

Long-term therapy of uremic osteodystrophy in adults with calcitriol.

Moorthy AV, Harrington AR, Mazess RB, Simpson DP.

Clin Nephrol. 1981 Aug;16(2):93-100.PMID: 6894893 [PubMed - indexed for MEDLINE]Related articles

[Effects of 1-alpha-hydroxyvitamin D 3 treatment of osteodystrophy in uremic patients treated with periodic hemodialysis]

Palmieri P, Albertazzi A, Cappelli P, Di Paolo B.

G Clin Med. 1981 Jul;62(7):443-60. Italian. No abstract available. PMID: 7308629 [PubMed - indexed for MEDLINE]Related articles

1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration.

Fournier A, Morinière PH, Oprisiu R, Yverneau-Hardy P, Westeel PF, Mazouz H, el Esper N, Ghazali A, Boudailliez B.

Nephron. 1995;71(3):254-83. Review.PMID: 8569975 [PubMed - indexed for MEDLINE]Related articles